02157.HK
Lepu Biopharma Co., Ltd.
HKSE · Healthcare · Biotechnology · CN
HKD 4.35
+0.69%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.7B | 910.7M | 367.8M | 225.4M | 15.6M |
| Cost of Revenue | 285.3M | 178.6M | 74.8M | 28.3M | 2.0M |
| Gross Profit | 1.4B | 732.1M | 293.0M | 197.1M | 13.6M |
| Operating Expenses | |||||
| R&D Expense | 591.6M | 335.6M | 437.7M | 458.1M | 524.3M |
| SG&A Expense | 680.0M | 354.5M | 237.9M | 130.0M | 140.6M |
| General & Admin Expense | 116.5M | 114.1M | 91.9M | 86.7M | 138.8M |
| Selling & Marketing Expense | 200.0M | 240.3M | 146.0M | 43.3M | 1.7M |
| Other Expenses | 215.9M | (45.4M) | 8.1M | (395.7M) | 53.2M |
| Total Operating Expenses | 1.5B | 644.7M | 683.7M | 192.3M | 718.0M |
| Cost and Expenses | 1.8B | 823.2M | 758.6M | 220.6M | 720.1M |
| Operating Income (EBIT) | (96.1M) | 87.4M | (390.8M) | 4.8M | (704.5M) |
| Non-Operating | |||||
| Interest Income | 12.1M | 12.0M | 4.7M | 6.7M | 8.2M |
| Interest Expense | 50.6M | 28.6M | 21.6M | 14.7M | 7.5M |
| Net Interest Income | (38.6M) | (16.5M) | (18.3M) | (8.0M) | 882.0K |
| Other Non-Op Income/Expense | 150.1M | 166.5M | (33.4M) | (35.1M) | 5.0M |
| Non-Operating Income (excl Interest) | (11.7M) | — | 5.1M | 20.4M | (12.5M) |
| EBT (Pre-Tax Income) | 54.0M | 253.9M | (424.2M) | (30.3M) | (699.4M) |
| Income Tax Expense | 1.8M | 1.7M | — | — | — |
| Bottom Line | |||||
| Net Income | 65.8M | 254.6M | (411.4M) | (22.1M) | (689.1M) |
| Earnings from Cont. Ops | 52.2M | 252.2M | (424.2M) | (30.3M) | (699.4M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 65.8M | 254.6M | (411.4M) | (22.1M) | (689.1M) |
| Per Share | |||||
| Basic EPS | HK$0.03 | HK$0.14 | (HK$0.24) | (HK$0.01) | (HK$0.42) |
| Diluted EPS | HK$0.03 | HK$0.14 | (HK$0.24) | (HK$0.01) | (HK$0.42) |
| Revenue Per Share | HK$0.93 | HK$0.52 | HK$0.22 | HK$0.14 | HK$0.01 |
| Shares | |||||
| Basic Shares Outstanding | 1.8B | 1.8B | 1.7B | 1.7B | 1.6B |
| Diluted Shares Outstanding | 1.8B | 1.8B | 1.7B | 1.7B | 1.6B |
| Profitability Metrics | |||||
| EBITDA | 41.1M | 178.7M | (311.9M) | 86.9M | (596.5M) |
| D&A | 125.4M | 91.3M | 83.9M | 102.6M | 95.4M |
| EBIT | (84.3M) | 87.4M | (395.9M) | (15.6M) | (692.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026